CITI/CALL/REGENERON PHARMACEUTICALS/900/0.01/19.06.25 | Market Closed - Börse Stuttgart 03:15:46 2024-05-23 am EDT | ||
| 1.7 EUR | -2.86% |
|
| Current month | +42.28% | ||
| 1 month | +34.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about REGENERON PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 1.7 | -2.86% |
| 24-05-22 | 1.75 | +3.55% |
| 24-05-21 | 1.69 | +1.20% |
| 24-05-20 | 1.67 | +5.03% |
| 24-05-17 | 1.59 | -5.36% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 03:15 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | REGENERON PHARMACEUTICALS, INC. |
| Issuer | 
Citi
|
| WKN | KH8MKM |
| ISIN | DE000KH8MKM0 |
| Date issued | 2023-08-07 |
| Strike | 900 $ |
| Maturity | 2025-06-19 (392 Days) |
| Parity | 100 : 1 |
| Emission price | 0.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.96 € |
|---|---|
| Lowest since issue | 0.82 € |
Company Profile
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
Ratings for Regeneron Pharmaceuticals, Inc.
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Regeneron Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
983.8
USD
Average target price
1,042
USD
Spread / Average Target
+5.91%
- Stock Market
- Warrants
- Warrant
